Ilona E Kammerl1, Angela Dann1, Alessandra Mossina1, Dorothee Brech2, Christina Lukas1, Oliver Vosyka1, Petra Nathan1, Thomas M Conlon3, Darcy E Wagner2, Hermen S Overkleeft4, Antje Prasse5, Ivan O Rosas6, Tobias Straub7, Susanne Krauss-Etschmann8,9, Melanie Königshoff1, Gerhard Preissler10, Hauke Winter10, Michael Lindner11, Rudolf Hatz10,11, Jürgen Behr1,11,12, Katharina Heinzelmann1, Ali Ö Yildirim3, Elfriede Noessner2, Oliver Eickelberg1, Silke Meiners1. 1. 1 Comprehensive Pneumology Center, University Hospital, Ludwig-Maximilians University, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany. 2. 2 Institute of Molecular Immunology, Helmholtz Zentrum München, Munich, Germany. 3. 3 Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, Member of the DZL, Neuherberg, Germany. 4. 4 Department of Bio-organic Synthesis, Leiden University, Leiden, the Netherlands. 5. 5 Department of Pneumology, Hannover Medical School, Hannover, Germany. 6. 6 Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 7. 7 Biomedical Center, Bioinformatics Unit, Ludwig-Maximilians University, Munich, Germany. 8. 8 Division of Experimental Asthma Research, Research Center Borstel, Airway Research Center North, Member of the DZL, Borstel, Germany. 9. 9 Institute of Experimental Medicine, Christian-Albrechts-Universität zu Kiel, Germany. 10. 10 Thoraxchirurgisches Zentrum, Klinik für Allgemeine-, Viszeral-, Transplantations-, Gefäß- und Thoraxchirurgie, Klinikum Großhadern, Ludwig-Maximilians-Universität, Member of the DZL, Munich, Germany. 11. 11 Asklepios Fachkliniken München-Gauting, Gauting, Germany; and. 12. 12 Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität, Member of the DZL, Munich, Germany.
Abstract
RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) and in particular smokers are more susceptible to respiratory infections contributing to acute exacerbations of disease. The immunoproteasome is a specialized type of proteasome destined to improve major histocompatibility complex (MHC) class I-mediated antigen presentation for the resolution of intracellular infections. OBJECTIVES: To characterize immunoproteasome function in COPD and its regulation by cigarette smoke. METHODS: Immunoproteasome expression and activity were determined in bronchoalveolar lavage (BAL) and lungs of human donors and patients with COPD or idiopathic pulmonary fibrosis (IPF), as well as in cigarette smoke-exposed mice. Smoke-mediated alterations of immunoproteasome activity and MHC I surface expression were analyzed in human blood-derived macrophages. Immunoproteasome-specific MHC I antigen presentation was evaluated in spleen and lung immune cells that had been smoke-exposed in vitro or in vivo. MEASUREMENTS AND MAIN RESULTS: Immunoproteasome and MHC I mRNA expression was reduced in BAL cells of patients with COPD and in isolated alveolar macrophages of patients with COPD or IPF. Exposure of immune cells to cigarette smoke extract in vitro reduced immunoproteasome activity and impaired immunoproteasome-specific MHC I antigen presentation. In vivo, acute cigarette smoke exposure dynamically regulated immunoproteasome function and MHC I antigen presentation in mouse BAL cells. End-stage COPD lungs showed markedly impaired immunoproteasome activities. CONCLUSIONS: We here show that the activity of the immunoproteasome is impaired by cigarette smoke resulting in reduced MHC I antigen presentation. Regulation of immunoproteasome function by cigarette smoke may thus alter adaptive immune responses and add to prolonged infections and exacerbations in COPD and IPF.
RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) and in particular smokers are more susceptible to respiratory infections contributing to acute exacerbations of disease. The immunoproteasome is a specialized type of proteasome destined to improve major histocompatibility complex (MHC) class I-mediated antigen presentation for the resolution of intracellular infections. OBJECTIVES: To characterize immunoproteasome function in COPD and its regulation by cigarette smoke. METHODS: Immunoproteasome expression and activity were determined in bronchoalveolar lavage (BAL) and lungs of human donors and patients with COPD or idiopathic pulmonary fibrosis (IPF), as well as in cigarette smoke-exposed mice. Smoke-mediated alterations of immunoproteasome activity and MHC I surface expression were analyzed in human blood-derived macrophages. Immunoproteasome-specific MHC I antigen presentation was evaluated in spleen and lung immune cells that had been smoke-exposed in vitro or in vivo. MEASUREMENTS AND MAIN RESULTS: Immunoproteasome and MHC I mRNA expression was reduced in BAL cells of patients with COPD and in isolated alveolar macrophages of patients with COPD or IPF. Exposure of immune cells to cigarette smoke extract in vitro reduced immunoproteasome activity and impaired immunoproteasome-specific MHC I antigen presentation. In vivo, acute cigarette smoke exposure dynamically regulated immunoproteasome function and MHC I antigen presentation in mouse BAL cells. End-stage COPD lungs showed markedly impaired immunoproteasome activities. CONCLUSIONS: We here show that the activity of the immunoproteasome is impaired by cigarette smoke resulting in reduced MHC I antigen presentation. Regulation of immunoproteasome function by cigarette smoke may thus alter adaptive immune responses and add to prolonged infections and exacerbations in COPD and IPF.
Entities:
Keywords:
MHC class I antigen presentation; alveolar macrophages; cigarette smoke; immunoproteasome
Authors: Jayshree Advani; Yashwanth Subbannayya; Krishna Patel; Aafaque Ahmad Khan; Arun H Patil; Ankit P Jain; Hitendra S Solanki; Aneesha Radhakrishnan; Sneha M Pinto; Nandini A Sahasrabuddhe; Joji K Thomas; Premendu P Mathur; Bipin G Nair; Xiaofei Chang; T S Keshava Prasad; David Sidransky; Harsha Gowda; Aditi Chatterjee Journal: OMICS Date: 2017-07
Authors: Geremy Clair; Lisa M Bramer; Ravi Misra; Matthew D McGraw; Soumyaroop Bhattacharya; Joseph A Kitzmiller; Song Feng; Vincent G Danna; Gautam Bandyopadhyay; Harsh Bhotika; Heidie L Huyck; Gail H Deutsch; Thomas J Mariani; James P Carson; Jeffrey A Whitsett; Gloria S Pryhuber; Joshua N Adkins; Charles Ansong Journal: Am J Respir Crit Care Med Date: 2022-01-15 Impact factor: 21.405
Authors: Kevin Baßler; Wataru Fujii; Theodore S Kapellos; Erika Dudkin; Nico Reusch; Ari Horne; Benedikt Reiz; Malte D Luecken; Collins Osei-Sarpong; Stefanie Warnat-Herresthal; Lorenzo Bonaguro; Jonas Schulte-Schrepping; Allon Wagner; Patrick Günther; Carmen Pizarro; Tina Schreiber; Rainer Knoll; Lisa Holsten; Charlotte Kröger; Elena De Domenico; Matthias Becker; Kristian Händler; Christian T Wohnhaas; Florian Baumgartner; Meike Köhler; Heidi Theis; Michael Kraut; Marc H Wadsworth; Travis K Hughes; Humberto J Ferreira; Emily Hinkley; Ines H Kaltheuner; Matthias Geyer; Christoph Thiele; Alex K Shalek; Andreas Feißt; Daniel Thomas; Henning Dickten; Marc Beyer; Patrick Baum; Nir Yosef; Anna C Aschenbrenner; Thomas Ulas; Jan Hasenauer; Fabian J Theis; Dirk Skowasch; Joachim L Schultze Journal: Front Immunol Date: 2022-07-28 Impact factor: 8.786
Authors: Agnieszka Strzelak; Aleksandra Ratajczak; Aleksander Adamiec; Wojciech Feleszko Journal: Int J Environ Res Public Health Date: 2018-05-21 Impact factor: 3.390
Authors: S Chen; I E Kammerl; O Vosyka; T Baumann; Y Yu; Y Wu; M Irmler; H S Overkleeft; J Beckers; O Eickelberg; S Meiners; T Stoeger Journal: Cell Death Differ Date: 2016-03-18 Impact factor: 15.828